QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results
SHANGHAI, Jan. 29, 2026 /PRNewswire/ -- QureBio Ltd., a clinical-stage biotech company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders,...